In 2012, the first potent and selective Menin–KMT2A interaction inhibitor, MI2‐2, was discovered, showing activity in reducing cellular proliferation and oncogenic gene expression in KMT2A‐rearranged leukemia.95, 101. Here, KMT2A is linked to leukemia.